Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer

Sharon Coleman, Aled Clayton, Malcolm D. Mason, Bharat Jasani, Malcolm Adams, Zsuzsanna Tabi

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Immunologic approaches are emerging as new treatment options in several types of cancer. However, whereas the ability of patients to develop potent CD8+ T-cell responses is crucial for efficient antitumor responses, immunocompetence and T-cell function are not tested routinely in patients entering immunotherapy. The objective of our study was to monitor T-cell function in advanced cancer and during chemotherapy. CD8+ T-cell function of 21 patients with advanced ovarian cancer (stages III-IV) was assessed by cytokine flow cytometry following stimulation of 42 PBMC samples with a panel of synthetic viral peptides in vitro, consisting of pan-Caucasian epitopes. CD8+ T-cell responses were significantly lower in patients with high levels (>200 units/mL) of Ca125 (marker of tumor load and progression) than in those with low Ca125 levels (P = 0.0013). In longitudinal studies of nine patients, chemotherapy was associated with decreasing Ca125 levels in seven cases and also with improvement or maintenance of CD8 + T-cell function in seven cases. After the full course of chemotherapy, five of nine patients in remission displayed potent CD8 + T-cell responses, whereas four of nine patients in progression displayed low or decreasing T-cell responses, pointing toward a correlation between T-cell function and clinical response. Our results show for the first time that CD8+ T-cell function is not permanently suppressed in advanced cancer and successful chemotherapy is associated with improved antigen-specific T-cell reactivity. We suggest that functional assays determining T-cell immunocompetence can be valuable tools for optimizing cancer immunotherapy for improved clinical success.

Original languageEnglish
Pages (from-to)7000-7006
Number of pages7
JournalCancer Research
Volume65
Issue number15
DOIs
Publication statusPublished - Aug 1 2005
Externally publishedYes

Fingerprint

Ovarian Neoplasms
T-Lymphocytes
Drug Therapy
Immunocompetence
Immunotherapy
Neoplasms
Tumor Burden
Longitudinal Studies
Epitopes
Flow Cytometry
Maintenance
Cytokines
Antigens
Peptides

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Coleman, S., Clayton, A., Mason, M. D., Jasani, B., Adams, M., & Tabi, Z. (2005). Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer. Cancer Research, 65(15), 7000-7006. https://doi.org/10.1158/0008-5472.CAN-04-3792

Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer. / Coleman, Sharon; Clayton, Aled; Mason, Malcolm D.; Jasani, Bharat; Adams, Malcolm; Tabi, Zsuzsanna.

In: Cancer Research, Vol. 65, No. 15, 01.08.2005, p. 7000-7006.

Research output: Contribution to journalArticle

Coleman, S, Clayton, A, Mason, MD, Jasani, B, Adams, M & Tabi, Z 2005, 'Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer', Cancer Research, vol. 65, no. 15, pp. 7000-7006. https://doi.org/10.1158/0008-5472.CAN-04-3792
Coleman, Sharon ; Clayton, Aled ; Mason, Malcolm D. ; Jasani, Bharat ; Adams, Malcolm ; Tabi, Zsuzsanna. / Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer. In: Cancer Research. 2005 ; Vol. 65, No. 15. pp. 7000-7006.
@article{9bca8c0768c1470b94f8af66304a1ed3,
title = "Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer",
abstract = "Immunologic approaches are emerging as new treatment options in several types of cancer. However, whereas the ability of patients to develop potent CD8+ T-cell responses is crucial for efficient antitumor responses, immunocompetence and T-cell function are not tested routinely in patients entering immunotherapy. The objective of our study was to monitor T-cell function in advanced cancer and during chemotherapy. CD8+ T-cell function of 21 patients with advanced ovarian cancer (stages III-IV) was assessed by cytokine flow cytometry following stimulation of 42 PBMC samples with a panel of synthetic viral peptides in vitro, consisting of pan-Caucasian epitopes. CD8+ T-cell responses were significantly lower in patients with high levels (>200 units/mL) of Ca125 (marker of tumor load and progression) than in those with low Ca125 levels (P = 0.0013). In longitudinal studies of nine patients, chemotherapy was associated with decreasing Ca125 levels in seven cases and also with improvement or maintenance of CD8 + T-cell function in seven cases. After the full course of chemotherapy, five of nine patients in remission displayed potent CD8 + T-cell responses, whereas four of nine patients in progression displayed low or decreasing T-cell responses, pointing toward a correlation between T-cell function and clinical response. Our results show for the first time that CD8+ T-cell function is not permanently suppressed in advanced cancer and successful chemotherapy is associated with improved antigen-specific T-cell reactivity. We suggest that functional assays determining T-cell immunocompetence can be valuable tools for optimizing cancer immunotherapy for improved clinical success.",
author = "Sharon Coleman and Aled Clayton and Mason, {Malcolm D.} and Bharat Jasani and Malcolm Adams and Zsuzsanna Tabi",
year = "2005",
month = "8",
day = "1",
doi = "10.1158/0008-5472.CAN-04-3792",
language = "English",
volume = "65",
pages = "7000--7006",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "15",

}

TY - JOUR

T1 - Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer

AU - Coleman, Sharon

AU - Clayton, Aled

AU - Mason, Malcolm D.

AU - Jasani, Bharat

AU - Adams, Malcolm

AU - Tabi, Zsuzsanna

PY - 2005/8/1

Y1 - 2005/8/1

N2 - Immunologic approaches are emerging as new treatment options in several types of cancer. However, whereas the ability of patients to develop potent CD8+ T-cell responses is crucial for efficient antitumor responses, immunocompetence and T-cell function are not tested routinely in patients entering immunotherapy. The objective of our study was to monitor T-cell function in advanced cancer and during chemotherapy. CD8+ T-cell function of 21 patients with advanced ovarian cancer (stages III-IV) was assessed by cytokine flow cytometry following stimulation of 42 PBMC samples with a panel of synthetic viral peptides in vitro, consisting of pan-Caucasian epitopes. CD8+ T-cell responses were significantly lower in patients with high levels (>200 units/mL) of Ca125 (marker of tumor load and progression) than in those with low Ca125 levels (P = 0.0013). In longitudinal studies of nine patients, chemotherapy was associated with decreasing Ca125 levels in seven cases and also with improvement or maintenance of CD8 + T-cell function in seven cases. After the full course of chemotherapy, five of nine patients in remission displayed potent CD8 + T-cell responses, whereas four of nine patients in progression displayed low or decreasing T-cell responses, pointing toward a correlation between T-cell function and clinical response. Our results show for the first time that CD8+ T-cell function is not permanently suppressed in advanced cancer and successful chemotherapy is associated with improved antigen-specific T-cell reactivity. We suggest that functional assays determining T-cell immunocompetence can be valuable tools for optimizing cancer immunotherapy for improved clinical success.

AB - Immunologic approaches are emerging as new treatment options in several types of cancer. However, whereas the ability of patients to develop potent CD8+ T-cell responses is crucial for efficient antitumor responses, immunocompetence and T-cell function are not tested routinely in patients entering immunotherapy. The objective of our study was to monitor T-cell function in advanced cancer and during chemotherapy. CD8+ T-cell function of 21 patients with advanced ovarian cancer (stages III-IV) was assessed by cytokine flow cytometry following stimulation of 42 PBMC samples with a panel of synthetic viral peptides in vitro, consisting of pan-Caucasian epitopes. CD8+ T-cell responses were significantly lower in patients with high levels (>200 units/mL) of Ca125 (marker of tumor load and progression) than in those with low Ca125 levels (P = 0.0013). In longitudinal studies of nine patients, chemotherapy was associated with decreasing Ca125 levels in seven cases and also with improvement or maintenance of CD8 + T-cell function in seven cases. After the full course of chemotherapy, five of nine patients in remission displayed potent CD8 + T-cell responses, whereas four of nine patients in progression displayed low or decreasing T-cell responses, pointing toward a correlation between T-cell function and clinical response. Our results show for the first time that CD8+ T-cell function is not permanently suppressed in advanced cancer and successful chemotherapy is associated with improved antigen-specific T-cell reactivity. We suggest that functional assays determining T-cell immunocompetence can be valuable tools for optimizing cancer immunotherapy for improved clinical success.

UR - http://www.scopus.com/inward/record.url?scp=14844293666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14844293666&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-04-3792

DO - 10.1158/0008-5472.CAN-04-3792

M3 - Article

VL - 65

SP - 7000

EP - 7006

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 15

ER -